RNS Number : 1627H
Cellular Goods PLC
02 August 2021
 

Press release

02 August 2021

 

Cellular Goods PLC

("Cellular Goods" or "the Company")

 Share disposal by significant shareholder

 

At the time of Cellular Goods' (LSE: CBX) listing on 26 February 2021, it disclosed that Mr John Story held 15,000,000 ordinary shares in the capital of the Company representing 3% of its issued share capital. Following enquiries made by the Company, Mr Story has informed Cellular Goods that he has disposed of his entire holding in the Company. No further details of the disposal have been provided to the Company under the disclosure rules concerning share transactions by a significant shareholder.  

 

For further information please contact:

 

Cellular Goods


Alexis Abraham

Chief Executive

Neil Thapar

Investor Relations

+44 207 031 6871

 

 

+44 787 645 5323

Tennyson Securities


Corporate Broker

Peter Krens

 

+44 207 186 9030

Novum Securities


Corporate Broker

Colin Rowbury

Jon Belliss

 

 

+44 207 399 9427 

Tancredi Intelligent Communication


Media Relations

Helen Humphrey

Edward Daly

Salamander Davoudi

cellulargoods@tancredigroup.com

 

+44 744 922 6720

+44 786 143 0057

+44 795 754 9906

 

About Cellular Goods PLC

 

Cellular Goods is a U.K.-based provider of premium consumer products based on biosynthetic cannabinoids. It was established in August 2018 to develop efficacy-led and research-backed cannabinoid products. The initial focus is on two product verticals: premium skincare and topical athletic recovery products to be launched from this autumn. These will be made available through partnerships with leading online and physical retailers and direct to consumers through the Company's website. www.cellulargoods.co

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPBMBTMTBMTJB